[Opinion of the Czech Atherosclerosis Society's committee (CSAT) on the ESC/EAS guidelines related to the diagnostics and treatment of dyslipidemias issued in 2011].

This position statement of the Executive Committee of the Czech Society for Atherosclerosis (CSAT) summarizes the most important aspects and novelties of the latest European guidelines for the management of dyslipidemia. In particular the position statement comments on: cardiovascular risk stratification, indications for plasma lipid and lipoprotein levels assessment as well as target lipid values, evaluation of current options for both lifestyle and pharmacological treatment of lipid metabolism disorders and, also, recommendation for laboratory monitoring of patients treated with lipid lowering agents. The statement deals with actual concepts of management of dyslipiemia in everyday practice, e.g. therapy of dyslipidemia in special patients´ groups. This statement does not replace the latest guidelines but focuses on the changes from the former guidelines for dyslipidemia management, published by CSAT in 2007.
AuthorsV Soška, H Vaverková, M Vráblík, V Bláha, R Cífková, T Freiberger, P Kraml, J Piťha, H Rosolová, T Stulc, Z Urbanová
JournalVnitr̆ní lékar̆ství (Vnitr Lek) Vol. 59 Issue 2 Pg. 120-6 (Feb 2013) ISSN: 0042-773X [Print] Czech Republic
Vernacular TitleStanovisko výboru ČSAT k doporučením ESC/EAS pro diagnostiku a léčbu dyslipidemií z roku 2011.
PMID23461401 (Publication Type: English Abstract, Journal Article)
  • Czech Republic
  • Dyslipidemias (diagnosis, therapy)
  • Humans
  • Practice Guidelines as Topic
  • Societies, Medical

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: